GBT - Biotech ETFs look to continue recent rally

Biotechnology exchange traded funds look to build upon their winning streak on Friday as investors observed a double-digit performance jump across a handful of popular funds over the past week. Healthcare as a sector has been the best performing S&P segment of the market over the past week returning investors 6.4%, which has lent additional support to the biotech market. One of the leaders in the space has been the SPDR S&P Biotech ETF (NYSEARCA:XBI), which is among the market’s largest biotech ETFs with $6.98B assets under management. In addition, the fund is attached with a 0.35% expense ratio and supports 136 holdings led by Twist Bioscience (TWST), Global Blood Therapeutics Inc (GBT), and Amicus Therapeutics (NASDAQ:FOLD) weighted at 1.44%, 1.39%, and 1.33% respectively. Furthermore, XBI intends to deliver the financial community access to large- and mid-cap stocks specific to a subsector of the health care market. While XBI is one of the

For further details see:

Biotech ETFs look to continue recent rally